Drug news

Seebri Breezhaler(Novartis) success in GLOW 2 study for COPD

Read time: 1 mins

Last updated:17th May 2012

Published:17th May 2012

Source: Pharmawand

Novartis and Vectura reported one-year data from the pivotal, Phase III GLOW 2 study, confirming that the inhaled long acting muscarinic receptor antagonist, NVA237 (glycopyrronium bromide), is superior to placebo and has similar efficacy to open-label tiotropium in the treatment of patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

FDA Advisory Committee meeting to review investigational MDMA-assisted therapy for PTSD

Lykos Therapeutics (formerly MAPS Public Benefit Corporation) announced that on June 4, 2024, the FDA Psychopharmacologic Drugs Advisory Committee ("PDAC") will review data supporting the new drug application ("NDA") for midomafetamine (MDMA) capsules used in combination with psychological intervention ("MDMA-assisted therapy") for adults with post-traumatic stress disorder ("PTSD")

1 mins

Drug news

UCB presents final open-label extension (fenfluramine) data at International Child Neurology Congress (ICNC) Annual Meeting.

UCB announced the final three-year open-label extension (OLE) study results of Fintepla (fenfluramine) in Dravet syndrome are being presented at the International Child Neurology Congress (ICNC), May 6-10, 2024, in Cape Town, South Africa

1 min

Drug news

Lilly statement on FDA Advisory Committee meeting on donanemab for early symptomatic Alzheimer’s disease

The FDA will convene an in-person meeting of the Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) on Monday, June 10, 2024, to discuss donanemab, which Eli Lilly and Company has submitted for the treatment of early symptomatic Alzheimer’s disease. The open public hearing portion of the meeting will be conducted virtually

1 min

See all news